Compile Data Set for Download or QSAR
maximum 50k data
Found 100 Enz. Inhib. hit(s) with all data for entry = 2248
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359101(US10220048, Compound AA11 | US10952992, No. AA11 |...)
Affinity DataIC50:  0.0100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359121(US10220048, Compound AA31 | US10952992, No. AA31 |...)
Affinity DataIC50:  0.0800nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359106(US10220048, Compound AA16 | US10952992, No. AA16 |...)
Affinity DataIC50:  0.0800nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359113(US10220048, Compound AA23 | US10952992, No. AA23 |...)
Affinity DataIC50:  0.0900nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359099(US10220048, Compound AA9 | US10952992, No. AA9 | U...)
Affinity DataIC50:  0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359118(US10220048, Compound AA28 | US10952992, No. AA28 |...)
Affinity DataIC50:  0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359104(US10220048, Compound AA14 | US10952992, No. AA14 |...)
Affinity DataIC50:  0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359117(US10220048, Compound AA27 | US10952992, No. AA27 |...)
Affinity DataIC50:  0.140nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359091(US10220048, Compound AA1 | US10220048, Compound AA...)
Affinity DataIC50:  0.157nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359096(US10220048, Compound AA6 | US10952992, No. AA6 | U...)
Affinity DataIC50:  0.162nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359187(US10220048, Compound AA97 | US10952992, No. AA97 |...)
Affinity DataIC50:  0.200nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359108(US10220048, Compound AA18 | US10952992, No. AA18 |...)
Affinity DataIC50:  0.200nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359100(US10220048, Compound AA10 | US10952992, No. AA10 |...)
Affinity DataIC50:  0.200nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359120(US10220048, Compound AA30 | US10952992, No. AA30 |...)
Affinity DataIC50:  0.200nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359178(US10220048, Compound AA88 | US10952992, No. AA88 |...)
Affinity DataIC50:  0.200nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359131(US10220048, Compound AA41 | US10952992, No. AA41 |...)
Affinity DataIC50:  0.240nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359109(US10220048, Compound AA19 | US10952992, No. AA19 |...)
Affinity DataIC50:  0.300nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359105(US10220048, Compound AA15 | US10952992, No. AA15 |...)
Affinity DataIC50:  0.300nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359130(US10220048, Compound AA40 | US10952992, No. AA40 |...)
Affinity DataIC50:  0.300nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359167(US10220048, Compound AA77 | US10952992, No. AA77 |...)
Affinity DataIC50:  0.300nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359138(US10220048, Compound AA48 | US10952992, No. AA48 |...)
Affinity DataIC50:  0.300nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359137(US10220048, Compound AA47 | US10952992, No. AA47 |...)
Affinity DataIC50:  0.300nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359115(US10220048, Compound AA25 | US10952992, No. AA25 |...)
Affinity DataIC50:  0.400nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359127(US10220048, Compound AA37 | US10952992, No. AA37 |...)
Affinity DataIC50:  0.400nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359188(US10220048, Compound AA98 | US10952992, No. AA98 |...)
Affinity DataIC50:  0.600nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359132(US10220048, Compound AA42 | US10220048, Compound A...)
Affinity DataIC50:  1nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359129(US10220048, Compound AA39 | US10952992, No. AA39 |...)
Affinity DataIC50:  1nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359119(US10220048, Compound AA29 | US10952992, No. AA29 |...)
Affinity DataIC50:  1nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359114(US10220048, Compound AA24 | US10952992, No. AA24 |...)
Affinity DataIC50:  1nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359107(US10220048, Compound AA17 | US10952992, No. AA17 |...)
Affinity DataIC50:  1nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359098(US10220048, Compound AA8 | US10952992, No. AA8 | U...)
Affinity DataIC50:  1nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359103(US10220048, Compound AA13 | US10952992, No. AA13 |...)
Affinity DataIC50:  1nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359189(US10220048, Compound AA99 | US10952992, No. AA99 |...)
Affinity DataIC50:  2nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359175(US10220048, Compound AA85 | US10952992, No. AA85 |...)
Affinity DataIC50:  2nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359182(US10220048, Compound AA92 | US10952992, No. AA92 |...)
Affinity DataIC50:  2nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359183(US10220048, Compound AA93 | US10952992, No. AA93 |...)
Affinity DataIC50:  2nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359122(US10220048, Compound AA32 | US10952992, No. AA32 |...)
Affinity DataIC50:  2nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359135(US10220048, Compound AA45 | US10952992, No. AA45 |...)
Affinity DataIC50:  3nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359185(US10220048, Compound AA95 | US10952992, No. AA95 |...)
Affinity DataIC50:  3nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359128(US10220048, Compound AA38 | US10952992, No. AA38 |...)
Affinity DataIC50:  3nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359179(US10220048, Compound AA89 | US10952992, No. AA89 |...)
Affinity DataIC50:  3nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359092(US10220048, Compound AA2 | US10952992, No. AA2 | U...)
Affinity DataIC50:  4nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359126(US10220048, Compound AA36 | US10952992, No. AA36 |...)
Affinity DataIC50: <5nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359125(US10220048, Compound AA35 | US10952992, No. AA35 |...)
Affinity DataIC50: <5nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359124(US10220048, Compound AA34 | US10952992, No. AA34 |...)
Affinity DataIC50:  5nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359102(US10220048, Compound AA12 | US10952992, No. AA12 |...)
Affinity DataIC50: <5nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359116(US10220048, Compound AA26 | US10952992, No. AA26 |...)
Affinity DataIC50: <5nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359094(US10220048, Compound AA4 | US10952992, No. AA4 | U...)
Affinity DataIC50: <5nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359110(US10220048, Compound AA20 | US10952992, No. AA20 |...)
Affinity DataIC50: <5nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM359112(US10220048, Compound AA22 | US10952992, No. AA22 |...)
Affinity DataIC50: <5nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 100 total ) | Next | Last >>
Jump to: